TOP TEN perturbations for 38866_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38866_at
Selected probe(set): 208406_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38866_at (208406_s_at) across 6674 perturbations tested by GENEVESTIGATOR:
T-helper activation study 1 (120min) / unstimulated helper T-cell sample
Relative Expression (log2-ratio):2.434824Number of Samples:2 / 2
Experimental | T-helper activation study 1 (120min) |
Alloantigen specific helper T-cells were stimulated for 120min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors. | |
Control | unstimulated helper T-cell sample |
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors. |
B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)
Relative Expression (log2-ratio):-1.9865026Number of Samples:4 / 4
Experimental | B-CLL study 11 (rolipram) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
Control | rolipram study 4 (normal T-cell; 20uM) |
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
T-helper activation study 1 (100min) / unstimulated helper T-cell sample
Relative Expression (log2-ratio):1.847518Number of Samples:2 / 2
Experimental | T-helper activation study 1 (100min) |
Alloantigen specific helper T-cells were stimulated for 100min with anti-CD3/anti-CD28/IL-2 (100U/ml). T-helper cells were sorted as CD4+ CD25- cells from peripheral blood of healthy donors. | |
Control | unstimulated helper T-cell sample |
Unstimulated alloantigen specific helper T-cell sample derived from sorted CD4+ CD25- cells from peripheral blood of healthy donors. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample
Relative Expression (log2-ratio):-1.8427391Number of Samples:4 / 4
Experimental | B-CLL study 11 (DMSO) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
Control | vehicle (DMSO) treated normal T-cell sample |
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
Treg activation study 1 (300min) / unstimulated regulatory T-cell sample
Relative Expression (log2-ratio):-1.759697Number of Samples:2 / 2
Experimental | Treg activation study 1 (300min) |
Regulatory T-cells were stimulated for 300min with anti-CD3/anti-CD28/IL-2 (100U/ml). Treg were sorted as CD4+ CD25high cells from peripheral blood of healthy donors. | |
Control | unstimulated regulatory T-cell sample |
Unstimulated regulatory T-cell sample derived from sorted CD4+ CD25high cells from peripheral blood of healthy donors. |
pediatric meningococcal sepsis study 1 (24h; blood) / normal blood sample
Relative Expression (log2-ratio):-1.7429514Number of Samples:3 / 3
Experimental | pediatric meningococcal sepsis study 1 (24h; blood) |
Blood samples collected from children with (suspected) meningococcal sepsis 24 hours after admission to the pediatric intensive care unit (PICU). | |
Control | normal blood sample |
Normal blood samples collected from healthy children admitted for elective minor non-infectious surgery or MRI. |
precursor-B-ALL study 3 (TEL-AML1) / T-ALL study 3
Relative Expression (log2-ratio):-1.7249584Number of Samples:15 / 29
Experimental | precursor-B-ALL study 3 (TEL-AML1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | T-ALL study 3 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
methyl methanesulfonate study 6 (320µM) / untreated TK6 cell sample
Relative Expression (log2-ratio):-1.685566Number of Samples:3 / 15
Experimental | methyl methanesulfonate study 6 (320µM) |
TK6 cells treated with 320µM methyl methanesulfonate for 24h. ATC code:--- | |
Control | untreated TK6 cell sample |
Untreated TK6 cell line. Cells where left untreated for 24h before harvesting. |
precursor-B-ALL study 3 (E2A-PBX1) / T-ALL study 3
Relative Expression (log2-ratio):-1.6639795Number of Samples:6 / 29
Experimental | precursor-B-ALL study 3 (E2A-PBX1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | T-ALL study 3 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |
precursor-B-ALL study 3 (BCR-ABL) / T-ALL study 3
Relative Expression (log2-ratio):-1.651474Number of Samples:4 / 29
Experimental | precursor-B-ALL study 3 (BCR-ABL) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(9;22)(q34;q11.2)/BCR-ABL1]. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). | |
Control | T-ALL study 3 |
Peripheral blood or bone marrow samples of pediatric patients with childhood T-ALL. Patients were part of the Nordic Society Of Pediatric Hematology And Oncology Group (NOPHO). |